Leptomeningeal Metastasis Clinical Trial
Official title:
Phase II Study of Proton Cranio-spinal Irradiation for Leptomeningeal Metastasis
Leptomeningeal metastasis is a rare but serious complication to cancer, with a grave prognosis. No efficient treatment exists. Recent data suggest that craniospinal radiotherapy lead to superior survival and CNS control compared to focal photon radiotherapy. We want to offer Danish patients the new treatment, but within a protocol, as this is new data with an new treatment principle
Patients with leptomeningeal metastasis from both solid and hematological cancers will be offered proton radiotherapy with 30 Gy in 10 fractions to the entire craniospinal axis. Patients will be followed with registration of side effects, neurology and MRI scans every 3 months until 1 year. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
Completed |
NCT04178343 -
Tomotherapy for Leptomeningeal Metastases
|
N/A | |
Recruiting |
NCT04425681 -
Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05598853 -
Intrathecal Double Checkpoint Inhibition
|
Phase 1 | |
Recruiting |
NCT02803619 -
A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis
|
N/A | |
Not yet recruiting |
NCT04148898 -
Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis
|
Phase 2 | |
Completed |
NCT04420598 -
DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease
|
Phase 2 | |
Completed |
NCT02071056 -
Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM)
|
||
Not yet recruiting |
NCT05805631 -
Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC
|
Phase 2 | |
Recruiting |
NCT05385185 -
Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer
|
Phase 2 | |
Terminated |
NCT04729348 -
Pembrolizumab And Lenvatinib In Leptomeningeal Metastases
|
Phase 2 | |
Recruiting |
NCT06304441 -
Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
|
N/A | |
Not yet recruiting |
NCT06296745 -
Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.
|
Phase 2 | |
Recruiting |
NCT04778800 -
A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)
|
N/A | |
Not yet recruiting |
NCT06282874 -
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
|
Phase 4 | |
Not yet recruiting |
NCT04356222 -
Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
|
Phase 4 | |
Not yet recruiting |
NCT04356118 -
Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
|
Phase 4 | |
Not yet recruiting |
NCT04944069 -
Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis
|
N/A | |
Withdrawn |
NCT03974204 -
Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.
|
N/A |